Skip to content
Contact us
our research

Ongoing Research & Publications

Our ongoing research and peer-reviewed publications reflect our commitment to advancing drugs for treatment-resistance and sharing knowledge with the global scientific community.
GLP1/GIP Agonist Research Study

GLP1/GIP Agonist Research Study

This study examines the in vitro effects of a soluble protein hydrolysate (SPH) on incretin receptor activity and pancreatic islet cell protection to explore the mechanisms underlying metabolic health in overweight individuals.

View publication
DRD2 Agonist Treatment Resistance in Restless Leg Syndrome (RLS)-44be-40a5-b89e-09a66780fa3e

DRD2 Agonist Treatment Resistance in Restless Leg Syndrome (RLS)

A study exploring the mechanism of DRD2 agonist treatment resistance and developing a co-therapy to treat resistant RLS through receptor gene regulation.

View study

Publications

Targeting Iron Dysregulation in Prostate Cancer with FT-002a Peptides

Targeting Iron Dysregulation in Prostate Cancer with FT-002a Peptides

Study exploring the role of HBCI peptides in normalizing iron metabolism to overcome androgen receptor (AR) resistance in prostate cancer.

Read publication
Marine Oligopeptides Enhance Prostate Cancer Treatment with AR Inhibitors

Marine Oligopeptides Enhance Prostate Cancer Treatment with AR Inhibitors

Clinical investigation highlighting the efficacy of FT-002a in restoring sensitivity to enzalutamide in AR-resistant prostate cancer models.

Read publication
Mechanisms of Iron Dysregulation in Cancer and Therapeutic Implications

Mechanisms of Iron Dysregulation in Cancer and Therapeutic Implications

Research outlining the mechanisms by which iron dysregulation contributes to treatment resistance and tumor progression in prostate cancer.

Read Publication